Rezafungin (Rezzayo): How the First Weekly-Dosed IV Antifungal Reshapes Invasive Candidiasis Management in

Why Did Echinocandin Therapy Need a Once-Weekly Option?

Before rezafungin's arrival, the three available echinocandins — caspofungin, micafungin, and anidulafungin — shared a common limitation: each demanded daily intravenous infusion for the full treatment course. For candidemia, guidelines typically recommend at least 14 days of therapy after the first negative blood culture, meaning patients often remained hospitalized for weeks primarily to receive their antifungal. Central venous catheter complications, nosocomial co-infections, and the psychological toll of prolonged hospital stays added to the disease burden well beyond the fungal infection itself.

Rezafungin was engineered to solve this problem through structural modifications to the echinocandin scaffold that dramatically slow metabolic clearance. Its terminal elimination half-life of roughly 130 hours — more than ten times that of caspofungin — means a single infusion on Monday can maintain inhibitory concentrations against Candida species through the following Sunday. This pharmacokinetic profile was confirmed in Phase 1 dose-ranging studies before the pivotal RESTORE trial was designed around the weekly regimen.

What Did the RESTORE Trial Demonstrate About Efficacy and Safety?

The RESTORE study was a Phase 3, randomized, double-blind, multinational trial that enrolled adults with documented candidemia or invasive candidiasis. Patients received either rezafungin (400 mg IV on Day 1, then 200 mg IV weekly) or caspofungin (70 mg IV on Day 1, then 50 mg IV daily), with the option to step down to oral fluconazole after initial IV therapy in the comparator arm. The primary endpoint — global clinical cure at Day 14, a composite of clinical and microbiological success — was met, confirming non-inferiority of the weekly regimen.

Safety data from RESTORE revealed an adverse-event spectrum consistent with the broader echinocandin class. Hypokalemia, pyrexia, and gastrointestinal symptoms were among the most commonly reported events in both arms. Importantly, hepatotoxicity signals were not elevated with rezafungin, a relevant consideration given that many patients with invasive candidiasis have underlying hepatic compromise from critical illness or prior azole exposure. The 30-day all-cause mortality rates were also similar between groups, reinforcing the clinical comparability of weekly and daily echinocandin strategies.

How Could Weekly Dosing Transform Hospital Discharge Planning?

Outpatient parenteral antimicrobial therapy (OPAT) has been standard practice for bacterial infections such as endocarditis and osteomyelitis for decades, but antifungal OPAT has lagged behind — largely because daily echinocandin infusions are logistically difficult to coordinate outside the hospital. Rezafungin changes this calculus. A patient who achieves clinical stability and blood culture clearance could theoretically be discharged with a plan to return once weekly for a brief infusion, rather than occupying an inpatient bed solely for IV access.

Health-economics modelling presented at infectious disease conferences has suggested that even modest reductions in length of stay — on the order of several days per candidemia episode — could translate into substantial per-patient cost savings given the high daily cost of intensive care and step-down unit beds. Real-world implementation will require coordination between hospital antimicrobial stewardship teams, outpatient infusion centres, and pharmacy services to ensure seamless weekly dosing, but early adopter institutions have already begun developing rezafungin-based discharge pathways.

What Role Does Rezafungin Play Against Emerging Candida Auris Resistance?

Candida auris has been classified as an urgent antimicrobial resistance threat by the U.S. Centers for Disease Control and Prevention and as a critical priority fungal pathogen by the World Health Organization. Its ability to persist on environmental surfaces, spread within healthcare facilities, and develop resistance to multiple antifungal classes simultaneously makes it uniquely dangerous. Some clinical isolates are resistant to azoles, polyenes, and even echinocandins, leaving vanishingly few therapeutic options.

Laboratory susceptibility testing has shown that rezafungin maintains low minimum inhibitory concentrations against the majority of C. auris isolates evaluated to date, including many that are fluconazole- and amphotericin B-resistant. Because rezafungin does not undergo significant cytochrome P450-mediated hepatic metabolism, it carries a lower risk of drug-drug interactions than azole antifungals — a meaningful advantage in the critically ill, polypharmacy-heavy populations most vulnerable to C. auris. Post-marketing surveillance programmes will be essential to track whether widespread rezafungin use selects for echinocandin-resistant C. auris lineages over time.